ID   PDPK1_HUMAN             Reviewed;         556 AA.
AC   O15530; H0Y4Z0; Q59EH6; Q6FI20; Q8IV52; Q9BRD5;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   12-OCT-2022, entry version 235.
DE   RecName: Full=3-phosphoinositide-dependent protein kinase 1;
DE            Short=hPDK1;
DE            EC=2.7.11.1;
GN   Name=PDPK1; Synonyms=PDK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN PHOSPHORYLATION OF
RP   PKB/AKT1.
RX   PubMed=9094314; DOI=10.1016/s0960-9822(06)00122-9;
RA   Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R.J.,
RA   Reese C.B., Cohen P.;
RT   "Characterization of a 3-phosphoinositide-dependent protein kinase which
RT   phosphorylates and activates protein kinase B alpha.";
RL   Curr. Biol. 7:261-269(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9368760; DOI=10.1016/s0960-9822(06)00336-8;
RA   Alessi D.R., Deak M., Casamayor A., Caudwell F.B., Morrice N.A.,
RA   Norman D.G., Gaffney P.R.J., Reese C.B., MacDougall C.N., Harbison D.,
RA   Ashworth A., Bownes M.;
RT   "3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and
RT   functional homology with the Drosophila DSTPK61 kinase.";
RL   Curr. Biol. 7:776-789(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Myeloid;
RX   PubMed=9445477; DOI=10.1126/science.279.5351.710;
RA   Stephens L.R., Anderson K.E., Stokoe D., Erdjument-Bromage H.,
RA   Painter G.F., Holmes A.B., Gaffney P.R.J., Reese C.B., McCormick F.,
RA   Tempst P., Coadwell W.J., Hawkins P.T.;
RT   "Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-
RT   trisphosphate-dependent activation of protein kinase B.";
RL   Science 279:710-714(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Brain, Kidney, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 60-75; 87-100; 184-199; 239-257 AND 284-293,
RP   PHOSPHORYLATION AT SER-241, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [9]
RP   MUTAGENESIS OF ARG-474, AND ALTERNATIVE SPLICING.
RX   PubMed=9637919; DOI=10.1016/s0960-9822(98)70274-x;
RA   Anderson K.E., Coadwell W.J., Stephens L.R., Hawkins P.T.;
RT   "Translocation of PDK-1 to the plasma membrane is important in allowing
RT   PDK-1 to activate protein kinase B.";
RL   Curr. Biol. 8:684-691(1998).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF PRKCZ.
RX   PubMed=9768361; DOI=10.1016/s0960-9822(98)70444-0;
RA   Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S.,
RA   Newton A.C., Schaffhausen B.S., Toker A.;
RT   "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.";
RL   Curr. Biol. 8:1069-1077(1998).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF PRKACA.
RX   PubMed=9707564; DOI=10.1073/pnas.95.17.9849;
RA   Cheng X., Ma Y., Moore M., Hemmings B.A., Taylor S.S.;
RT   "Phosphorylation and activation of cAMP-dependent protein kinase by
RT   phosphoinositide-dependent protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9849-9854(1998).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KB1.
RX   PubMed=9445476; DOI=10.1126/science.279.5351.707;
RA   Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C.,
RA   Hemmings B.A., Thomas G.;
RT   "Phosphorylation and activation of p70s6k by PDK1.";
RL   Science 279:707-710(1998).
RN   [13]
RP   PHOSPHORYLATION AT SER-25; SER-241; SER-393; SER-396 AND SER-410, AND
RP   MUTAGENESIS OF SER-25; SER-241; SER-393; SER-396 AND SER-410.
RX   PubMed=10455013; DOI=10.1042/bj3420287;
RA   Casamayor A., Morrice N.A., Alessi D.R.;
RT   "Phosphorylation of Ser-241 is essential for the activity of 3-
RT   phosphoinositide-dependent protein kinase-1: identification of five sites
RT   of phosphorylation in vivo.";
RL   Biochem. J. 342:287-292(1999).
RN   [14]
RP   MUTAGENESIS OF ALA-277.
RX   PubMed=10364160; DOI=10.1101/gad.13.11.1438;
RA   Paradis S., Ailion M., Toker A., Thomas J.H., Ruvkun G.;
RT   "A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase
RT   signals that regulate diapause in Caenorhabditis elegans.";
RL   Genes Dev. 13:1438-1452(1999).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KA3.
RX   PubMed=10480933; DOI=10.1074/jbc.274.38.27168;
RA   Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S.,
RA   Froedin M.;
RT   "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-
RT   phosphoinositide-dependent protein kinase-1.";
RL   J. Biol. Chem. 274:27168-27176(1999).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF PAK1, AND INTERACTION WITH PAK1.
RX   PubMed=10995762; DOI=10.1074/jbc.m006553200;
RA   King C.C., Gardiner E.M., Zenke F.T., Bohl B.P., Newton A.C.,
RA   Hemmings B.A., Bokoch G.M.;
RT   "p21-activated kinase (PAK1) is phosphorylated and activated by 3-
RT   phosphoinositide-dependent kinase-1 (PDK1).";
RL   J. Biol. Chem. 275:41201-41209(2000).
RN   [17]
RP   PHOSPHORYLATION AT TYR-9; SER-241; TYR-373 AND TYR-376, AND MUTAGENESIS OF
RP   TYR-9; TYR-373 AND TYR-376.
RX   PubMed=11481331; DOI=10.1074/jbc.m105916200;
RA   Park J., Hill M.M., Hess D., Brazil D.P., Hofsteenge J., Hemmings B.A.;
RT   "Identification of tyrosine phosphorylation sites on 3-phosphoinositide-
RT   dependent protein kinase-1 (PDK1) and their role in regulating kinase
RT   activity.";
RL   J. Biol. Chem. 276:37459-37471(2001).
RN   [18]
RP   ACTIVITY REGULATION, AND INTERACTION WITH YWHAH AND YWHAQ.
RX   PubMed=12177059; DOI=10.1074/jbc.m205141200;
RA   Sato S., Fujita N., Tsuruo T.;
RT   "Regulation of kinase activity of 3-phosphoinositide-dependent protein
RT   kinase-1 by binding to 14-3-3.";
RL   J. Biol. Chem. 277:39360-39367(2002).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF PKB/AKT1.
RX   PubMed=12167717; DOI=10.1128/mcb.22.17.6247-6260.2002;
RA   Scheid M.P., Marignani P.A., Woodgett J.R.;
RT   "Multiple phosphoinositide 3-kinase-dependent steps in activation of
RT   protein kinase B.";
RL   Mol. Cell. Biol. 22:6247-6260(2002).
RN   [20]
RP   FUNCTION, PHOSPHORYLATION AT TYR-9; TYR-373 AND TYR-376 BY SRC, INTERACTION
RP   WITH PTK2B, AND SUBCELLULAR LOCATION.
RX   PubMed=14585963; DOI=10.1128/mcb.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal
RT   adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF SGK3, AND INTERACTION WITH SGK3.
RX   PubMed=14604990; DOI=10.1074/jbc.m309653200;
RA   Nilsen T., Slagsvold T., Skjerpen C.S., Brech A., Stenmark H., Olsnes S.;
RT   "Peroxisomal targeting as a tool for assaying protein-protein interactions
RT   in the living cell: cytokine-independent survival kinase (CISK) binds PDK-1
RT   in vivo in a phosphorylation-dependent manner.";
RL   J. Biol. Chem. 279:4794-4801(2004).
RN   [22]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH GRB14.
RX   PubMed=15210700; DOI=10.1074/jbc.m405340200;
RA   King C.C., Newton A.C.;
RT   "The adaptor protein Grb14 regulates the localization of 3-
RT   phosphoinositide-dependent kinase-1.";
RL   J. Biol. Chem. 279:37518-37527(2004).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1, AND INTERACTION WITH PKN2.
RX   PubMed=10226025; DOI=10.1016/s0960-9822(99)80186-9;
RA   Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P., Currie R.,
RA   Downes C.P., Alessi D.R.;
RT   "PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived
RT   from the carboxyl terminus of PRK2.";
RL   Curr. Biol. 9:393-404(1999).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=15209375; DOI=10.1016/j.semcdb.2003.12.022;
RA   Mora A., Komander D., van Aalten D.M., Alessi D.R.;
RT   "PDK1, the master regulator of AGC kinase signal transduction.";
RL   Semin. Cell Dev. Biol. 15:161-170(2004).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF IKKB, AND INTERACTION WITH IKKB.
RX   PubMed=16207722; DOI=10.1074/jbc.m506235200;
RA   Tanaka H., Fujita N., Tsuruo T.;
RT   "3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta
RT   (IkkB) phosphorylation activates NF-kappaB signaling.";
RL   J. Biol. Chem. 280:40965-40973(2005).
RN   [26]
RP   FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH STRAP.
RX   PubMed=16251192; DOI=10.1074/jbc.m507539200;
RA   Seong H.A., Jung H., Choi H.S., Kim K.T., Ha H.;
RT   "Regulation of transforming growth factor-beta signaling and PDK1 kinase
RT   activity by physical interaction between PDK1 and serine-threonine kinase
RT   receptor-associated protein.";
RL   J. Biol. Chem. 280:42897-42908(2005).
RN   [27]
RP   PHOSPHORYLATION AT SER-396, AND SUBCELLULAR LOCATION.
RX   PubMed=15743829; DOI=10.1128/mcb.25.6.2347-2363.2005;
RA   Scheid M.P., Parsons M., Woodgett J.R.;
RT   "Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear
RT   translocation.";
RL   Mol. Cell. Biol. 25:2347-2363(2005).
RN   [28]
RP   PHOSPHORYLATION AT TYR-9; TYR-373 AND TYR-376 BY INSR, AND INTERACTION WITH
RP   INSR.
RX   PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005;
RA   Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V.,
RA   Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P.,
RA   Beguinot F.;
RT   "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the
RT   insulin receptor is necessary for insulin metabolic signaling.";
RL   Mol. Cell. Biol. 25:10803-10814(2005).
RN   [29]
RP   PHOSPHORYLATION AT SER-241 AND THR-513.
RX   PubMed=16780920; DOI=10.1016/j.bioorg.2006.05.002;
RA   Gao X., Harris T.K.;
RT   "Role of the PH domain in regulating in vitro autophosphorylation events
RT   required for reconstitution of PDK1 catalytic activity.";
RL   Bioorg. Chem. 34:200-223(2006).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH SMAD2; SMAD3; SMAD4 AND SMAD7.
RX   PubMed=17327236; DOI=10.1074/jbc.m609279200;
RA   Seong H.A., Jung H., Kim K.T., Ha H.;
RT   "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth
RT   factor-beta-induced signaling in a kinase-dependent manner through physical
RT   interaction with Smad proteins.";
RL   J. Biol. Chem. 282:12272-12289(2007).
RN   [31]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17371830; DOI=10.1083/jcb.200607053;
RA   Primo L., di Blasio L., Roca C., Droetto S., Piva R., Schaffhausen B.,
RA   Bussolino F.;
RT   "Essential role of PDK1 in regulating endothelial cell migration.";
RL   J. Cell Biol. 176:1035-1047(2007).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF PKN2.
RX   PubMed=18835241; DOI=10.1016/j.abb.2008.09.008;
RA   Lim W.G., Chen X., Liu J.P., Tan B.J., Zhou S., Smith A., Lees N., Hou L.,
RA   Gu F., Yu X.Y., Du Y., Smith D., Verma C., Liu K., Duan W.;
RT   "The C-terminus of PRK2/PKNgamma is required for optimal activation by RhoA
RT   in a GTP-dependent manner.";
RL   Arch. Biochem. Biophys. 479:170-178(2008).
RN   [33]
RP   INTERACTION WITH NPRL2, AND ACTIVITY REGULATION.
RX   PubMed=18616680; DOI=10.1111/j.1349-7006.2008.00874.x;
RA   Kurata A., Katayama R., Watanabe T., Tsuruo T., Fujita N.;
RT   "TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine
RT   phosphorylation and its downstream signaling.";
RL   Cancer Sci. 99:1827-1834(2008).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=18802401; DOI=10.4161/cc.7.19.6810;
RA   Bayascas J.R.;
RT   "Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1
RT   (PDK1) signalling pathways.";
RL   Cell Cycle 7:2978-2982(2008).
RN   [35]
RP   INTERACTION WITH SRC; RASA1 AND CRK, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=18024423; DOI=10.1074/jbc.m706361200;
RA   Yang K.J., Shin S., Piao L., Shin E., Li Y., Park K.A., Byun H.S., Won M.,
RA   Hong J., Kweon G.R., Hur G.M., Seok J.H., Chun T., Brazil D.P.,
RA   Hemmings B.A., Park J.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src
RT   involves tyrosine phosphorylation of PDK1 and Src homology 2 domain
RT   binding.";
RL   J. Biol. Chem. 283:1480-1491(2008).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PTPN6.
RX   PubMed=19591923; DOI=10.1016/j.cellsig.2009.06.010;
RA   Sephton C.F., Zhang D., Lehmann T.M., Pennington P.R., Scheid M.P.,
RA   Mousseau D.D.;
RT   "The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is
RT   dependent on its association with the protein tyrosine phosphatase SHP-1.";
RL   Cell. Signal. 21:1634-1644(2009).
RN   [37]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19276999; DOI=10.1097/wnr.0b013e328329a41a;
RA   Alajajian B.B., Fletcher L., Isgor E., Jimenez D.F., Digicaylioglu M.;
RT   "IGF-I regulated phosphorylation and translocation of PDK-1 in neurons.";
RL   NeuroReport 20:579-583(2009).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [39]
RP   PHOSPHORYLATION AT THR-354 BY MELK, PHOSPHORYLATION AT SER-394 AND SER-398
RP   BY MAP3K5, AND MUTAGENESIS OF THR-354; SER-394 AND SER-398.
RX   PubMed=22544756; DOI=10.1074/jbc.m111.331827;
RA   Seong H.A., Jung H., Manoharan R., Ha H.;
RT   "PDK1 phosphorylation at Thr354 by murine protein serine/threonine kinase
RT   38 contributes to the negative regulation of PDK1 activity.";
RL   J. Biol. Chem. 287:20811-20822(2012).
RN   [40]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP4.
RX   PubMed=22347420; DOI=10.1371/journal.pone.0031003;
RA   Uras I.Z., List T., Nijman S.M.;
RT   "Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master
RT   growth factor signaling kinase PDK1.";
RL   PLoS ONE 7:E31003-E31003(2012).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 71-359 IN COMPLEX WITH ATP.
RX   PubMed=12169624; DOI=10.1093/emboj/cdf437;
RA   Biondi R.M., Komander D., Thomas C.C., Lizcano J.M., Deak M., Alessi D.R.,
RA   van Aalten D.M.;
RT   "High resolution crystal structure of the human PDK1 catalytic domain
RT   defines the regulatory phosphopeptide docking site.";
RL   EMBO J. 21:4219-4228(2002).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 51-360 IN COMPLEX WITH ATP.
RX   PubMed=15741170; DOI=10.1074/jbc.m500977200;
RA   Komander D., Kular G., Deak M., Alessi D.R., van Aalten D.M.;
RT   "Role of T-loop phosphorylation in PDK1 activation, stability, and
RT   substrate binding.";
RL   J. Biol. Chem. 280:18797-18802(2005).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 74-359, AND PHOSPHORYLATION AT
RP   SER-241.
RX   PubMed=15772071; DOI=10.1074/jbc.m501367200;
RA   Feldman R.I., Wu J.M., Polokoff M.A., Kochanny M.J., Dinter H., Zhu D.,
RA   Biroc S.L., Alicke B., Bryant J., Yuan S., Buckman B.O., Lentz D.,
RA   Ferrer M., Whitlow M., Adler M., Finster S., Chang Z., Arnaiz D.O.;
RT   "Novel small molecule inhibitors of 3-phosphoinositide-dependent
RT   kinase-1.";
RL   J. Biol. Chem. 280:19867-19874(2005).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 409-556, SUBUNIT, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF THR-513.
RX   PubMed=20978239; DOI=10.1126/scisignal.2000738;
RA   Masters T.A., Calleja V., Armoogum D.A., Marsh R.J., Applebee C.J.,
RA   Laguerre M., Bain A.J., Larijani B.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by
RT   homodimerization in live cells.";
RL   Sci. Signal. 3:RA78-RA78(2010).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.43 ANGSTROMS) OF 51-359 IN COMPLEX WITH ATP, AND
RP   DOMAIN.
RX   PubMed=22999883; DOI=10.1016/j.chembiol.2012.07.017;
RA   Busschots K., Lopez-Garcia L.A., Lammi C., Stroba A., Zeuzem S., Piiper A.,
RA   Alzari P.M., Neimanis S., Arencibia J.M., Engel M., Schulze J.O.,
RA   Biondi R.M.;
RT   "Substrate-selective inhibition of protein kinase PDK1 by small compounds
RT   that bind to the PIF-pocket allosteric docking site.";
RL   Chem. Biol. 19:1152-1163(2012).
CC   -!- FUNCTION: Serine/threonine kinase which acts as a master kinase,
CC       phosphorylating and activating a subgroup of the AGC family of protein
CC       kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2,
CC       PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal
CC       protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent
CC       protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and
CC       glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated
CC       kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central
CC       role in the transduction of signals from insulin by providing the
CC       activating phosphorylation to PKB/AKT1, thus propagating the signal to
CC       downstream targets controlling cell proliferation and survival, as well
CC       as glucose and amino acid uptake and storage. Negatively regulates the
CC       TGF-beta-induced signaling by: modulating the association of SMAD3 and
CC       SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and
CC       SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the
CC       translocation of SMAD7 from the nucleus to the cytoplasm in response to
CC       TGF-beta. Activates PPARG transcriptional activity and promotes
CC       adipocyte differentiation. Activates the NF-kappa-B pathway via
CC       phosphorylation of IKKB. The tyrosine phosphorylated form is crucial
CC       for the regulation of focal adhesions by angiotensin II. Controls
CC       proliferation, survival, and growth of developing pancreatic cells.
CC       Participates in the regulation of Ca(2+) entry and Ca(2+)-activated
CC       K(+) channels of mast cells. Essential for the motility of vascular
CC       endothelial cells (ECs) and is involved in the regulation of their
CC       chemotaxis. Plays a critical role in cardiac homeostasis by serving as
CC       a dual effector for cell survival and beta-adrenergic response. Plays
CC       an important role during thymocyte development by regulating the
CC       expression of key nutrient receptors on the surface of pre-T cells and
CC       mediating Notch-induced cell growth and proliferative responses.
CC       Provides negative feedback inhibition to toll-like receptor-mediated
CC       NF-kappa-B activation in macrophages. Isoform 3 is catalytically
CC       inactive. {ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:10480933,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:12167717,
CC       ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:14604990,
CC       ECO:0000269|PubMed:16207722, ECO:0000269|PubMed:16251192,
CC       ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:17371830,
CC       ECO:0000269|PubMed:18835241, ECO:0000269|PubMed:9094314,
CC       ECO:0000269|PubMed:9445476, ECO:0000269|PubMed:9707564,
CC       ECO:0000269|PubMed:9768361}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Homodimerization regulates its activity by
CC       maintaining the kinase in an autoinhibitory conformation. NPRL2 down-
CC       regulates its activity by interfering with tyrosine phosphorylation at
CC       the Tyr-9, Tyr-373 and Tyr-376 residues. The 14-3-3 protein YWHAQ acts
CC       as a negative regulator by association with the residues surrounding
CC       the Ser-241 residue. STRAP positively regulates its activity by
CC       enhancing its autophosphorylation and by stimulating its dissociation
CC       from YWHAQ. SMAD2, SMAD3, SMAD4 and SMAD7 also positively regulate its
CC       activity by stimulating its dissociation from YWHAQ. Activated by
CC       phosphorylation on Tyr-9, Tyr-373 and Tyr-376 by INSR in response to
CC       insulin. {ECO:0000269|PubMed:12177059, ECO:0000269|PubMed:16251192,
CC       ECO:0000269|PubMed:18616680, ECO:0000269|PubMed:20978239}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer.
CC       Interacts with NPRL2, PPARG, PAK1, PTK2B, GRB14, PKN1 (via C-terminus),
CC       STRAP and IKKB. The Tyr-9 phosphorylated form interacts with SRC, RASA1
CC       and CRK (via their SH2 domains). Interacts with SGK3 in a
CC       phosphorylation-dependent manner. The tyrosine-phosphorylated form
CC       interacts with PTPN6. The Ser-241 phosphorylated form interacts with
CC       YWHAH and YWHAQ. Binds INSR in response to insulin. Interacts (via PH
CC       domain) with SMAD3, SMAD4 and SMAD7. Interacts with PKN2; the
CC       interaction stimulates PDPK1 autophosphorylation, its PI(3,4,5)P3-
CC       dependent kinase activity toward 'Ser-473' of AKT1 but also activates
CC       its kinase activity toward PRKCD and PRKCZ.
CC       {ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:10995762,
CC       ECO:0000269|PubMed:12177059, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:14604990, ECO:0000269|PubMed:15210700,
CC       ECO:0000269|PubMed:16207722, ECO:0000269|PubMed:16251192,
CC       ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:17327236,
CC       ECO:0000269|PubMed:18024423, ECO:0000269|PubMed:18616680,
CC       ECO:0000269|PubMed:19591923, ECO:0000269|PubMed:20978239}.
CC   -!- INTERACTION:
CC       O15530; P31749: AKT1; NbExp=4; IntAct=EBI-717097, EBI-296087;
CC       O15530; Q00005: PPP2R2B; NbExp=8; IntAct=EBI-717097, EBI-1052159;
CC       O15530; O75385: ULK1; NbExp=2; IntAct=EBI-717097, EBI-908831;
CC       O15530-4; P54252: ATXN3; NbExp=3; IntAct=EBI-9087775, EBI-946046;
CC       O15530-4; P42858: HTT; NbExp=6; IntAct=EBI-9087775, EBI-466029;
CC       O15530-4; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-9087775, EBI-1055254;
CC       O15530-4; Q8IUH5: ZDHHC17; NbExp=3; IntAct=EBI-9087775, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane; Peripheral
CC       membrane protein. Cell junction, focal adhesion. Note=Tyrosine
CC       phosphorylation seems to occur only at the cell membrane. Translocates
CC       to the cell membrane following insulin stimulation by a mechanism that
CC       involves binding to GRB14 and INSR. SRC and HSP90 promote its
CC       localization to the cell membrane. Its nuclear localization is
CC       dependent on its association with PTPN6 and its phosphorylation at Ser-
CC       396. Restricted to the nucleus in neuronal cells while in non-neuronal
CC       cells it is found in the cytoplasm. The Ser-241 phosphorylated form is
CC       distributed along the perinuclear region in neuronal cells while in
CC       non-neuronal cells it is found in both the nucleus and the cytoplasm.
CC       IGF1 transiently increases phosphorylation at Ser-241 of neuronal
CC       PDPK1, resulting in its translocation to other cellular compartments.
CC       The tyrosine-phosphorylated form colocalizes with PTK2B in focal
CC       adhesions after angiotensin II stimulation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O15530-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15530-2; Sequence=VSP_004894;
CC       Name=3;
CC         IsoId=O15530-3; Sequence=VSP_004895;
CC       Name=4;
CC         IsoId=O15530-4; Sequence=VSP_041902;
CC       Name=5;
CC         IsoId=O15530-5; Sequence=VSP_044796;
CC   -!- TISSUE SPECIFICITY: Appears to be expressed ubiquitously. The Tyr-9
CC       phosphorylated form is markedly increased in diseased tissue compared
CC       with normal tissue from lung, liver, colon and breast.
CC       {ECO:0000269|PubMed:18024423}.
CC   -!- INDUCTION: Stimulated by insulin, and the oxidants hydrogen peroxide
CC       and peroxovanadate.
CC   -!- DOMAIN: The PH domain plays a pivotal role in the localization and
CC       nuclear import of PDPK1 and is also essential for its homodimerization.
CC   -!- DOMAIN: The PIF-pocket is a small lobe in the catalytic domain required
CC       by the enzyme for the binding to the hydrophobic motif of its
CC       substrates. It is an allosteric regulatory site that can accommodate
CC       small compounds acting as allosteric inhibitors.
CC       {ECO:0000305|PubMed:22999883}.
CC   -!- PTM: Phosphorylation on Ser-241 in the activation loop is required for
CC       full activity. PDPK1 itself can autophosphorylate Ser-241, leading to
CC       its own activation. Autophosphorylation is inhibited by the apoptotic
CC       C-terminus cleavage product of PKN2 (By similarity). Tyr-9
CC       phosphorylation is critical for stabilization of both PDPK1 and the
CC       PDPK1/SRC complex via HSP90-mediated protection of PDPK1 degradation.
CC       Angiotensin II stimulates the tyrosine phosphorylation of PDPK1 in
CC       vascular smooth muscle in a calcium- and SRC-dependent manner.
CC       Phosphorylated on Tyr-9, Tyr-373 and Tyr-376 by INSR in response to
CC       insulin. Palmitate negatively regulates autophosphorylation at Ser-241
CC       and palmitate-induced phosphorylation at Ser-529 and Ser-501 by
CC       PKC/PRKCQ negatively regulates its ability to phosphorylate PKB/AKT1.
CC       Phosphorylation at Thr-354 by MELK partially inhibits kinase activity,
CC       the inhibition is cooperatively enhanced by phosphorylation at Ser-394
CC       and Ser-398 by MAP3K5. {ECO:0000250, ECO:0000269|PubMed:10455013,
CC       ECO:0000269|PubMed:11481331, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:15743829, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:16780920, ECO:0000269|PubMed:22544756,
CC       ECO:0000269|Ref.8}.
CC   -!- PTM: Autophosphorylated; autophosphorylation is inhibited by the
CC       apoptotic C-terminus cleavage product of PKN2. {ECO:0000250}.
CC   -!- PTM: Monoubiquitinated in the kinase domain, deubiquitinated by USP4.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PDPK1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93072.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF017995; AAC51825.1; -; mRNA.
DR   EMBL; Y15056; CAA75341.1; -; mRNA.
DR   EMBL; CR536517; CAG38755.1; -; mRNA.
DR   EMBL; AB209835; BAD93072.1; ALT_INIT; mRNA.
DR   EMBL; AC093525; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141586; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006339; AAH06339.2; -; mRNA.
DR   EMBL; BC012103; AAH12103.1; -; mRNA.
DR   EMBL; BC033494; AAH33494.1; -; mRNA.
DR   CCDS; CCDS10472.1; -. [O15530-1]
DR   CCDS; CCDS10473.1; -. [O15530-4]
DR   CCDS; CCDS58411.1; -. [O15530-5]
DR   RefSeq; NP_001248745.1; NM_001261816.1. [O15530-5]
DR   RefSeq; NP_002604.1; NM_002613.4. [O15530-1]
DR   RefSeq; NP_112558.2; NM_031268.5. [O15530-4]
DR   PDB; 1H1W; X-ray; 2.00 A; A=71-359.
DR   PDB; 1OKY; X-ray; 2.30 A; A=51-360.
DR   PDB; 1OKZ; X-ray; 2.51 A; A=51-360.
DR   PDB; 1UU3; X-ray; 1.70 A; A=51-360.
DR   PDB; 1UU7; X-ray; 1.90 A; A=51-360.
DR   PDB; 1UU8; X-ray; 2.50 A; A=51-360.
DR   PDB; 1UU9; X-ray; 1.95 A; A=72-357.
DR   PDB; 1UVR; X-ray; 2.81 A; A=71-359.
DR   PDB; 1W1D; X-ray; 1.50 A; A=409-556.
DR   PDB; 1W1G; X-ray; 1.45 A; A=409-556.
DR   PDB; 1W1H; X-ray; 1.45 A; A/B/C/D=409-556.
DR   PDB; 1Z5M; X-ray; 2.17 A; A=74-359.
DR   PDB; 2BIY; X-ray; 1.95 A; A=51-360.
DR   PDB; 2PE0; X-ray; 2.35 A; A=74-359.
DR   PDB; 2PE1; X-ray; 2.14 A; A=74-359.
DR   PDB; 2PE2; X-ray; 2.13 A; A=74-359.
DR   PDB; 2R7B; X-ray; 2.70 A; A=48-359.
DR   PDB; 2VKI; X-ray; 1.80 A; A=409-556.
DR   PDB; 2XCH; X-ray; 2.00 A; A=51-359.
DR   PDB; 2XCK; X-ray; 2.30 A; A=51-359.
DR   PDB; 3H9O; X-ray; 2.30 A; A=51-359.
DR   PDB; 3HRC; X-ray; 1.91 A; A=50-359.
DR   PDB; 3HRF; X-ray; 1.90 A; A=50-359.
DR   PDB; 3ION; X-ray; 2.40 A; A=48-359.
DR   PDB; 3IOP; X-ray; 2.20 A; A=48-359.
DR   PDB; 3NAX; X-ray; 1.75 A; A=66-362.
DR   PDB; 3NAY; X-ray; 2.60 A; A/B=66-362.
DR   PDB; 3NUN; X-ray; 2.20 A; A=67-358.
DR   PDB; 3NUS; X-ray; 2.75 A; A=73-358.
DR   PDB; 3NUU; X-ray; 1.98 A; A=73-358.
DR   PDB; 3NUY; X-ray; 2.10 A; A=73-358.
DR   PDB; 3ORX; X-ray; 2.20 A; A/B/C/D/E/F/G/H=51-359.
DR   PDB; 3ORZ; X-ray; 2.00 A; A/B/C/D=51-359.
DR   PDB; 3OTU; X-ray; 2.10 A; A=51-359.
DR   PDB; 3PWY; X-ray; 3.50 A; A=51-359.
DR   PDB; 3QC4; X-ray; 1.80 A; A/B=51-359.
DR   PDB; 3QCQ; X-ray; 2.50 A; A=48-359.
DR   PDB; 3QCS; X-ray; 2.49 A; A=48-359.
DR   PDB; 3QCX; X-ray; 2.30 A; A=48-359.
DR   PDB; 3QCY; X-ray; 2.20 A; A=48-359.
DR   PDB; 3QD0; X-ray; 1.99 A; A=48-359.
DR   PDB; 3QD3; X-ray; 2.00 A; A=48-359.
DR   PDB; 3QD4; X-ray; 2.30 A; A=48-359.
DR   PDB; 3RCJ; X-ray; 1.70 A; A=50-359.
DR   PDB; 3RWP; X-ray; 1.92 A; A=51-359.
DR   PDB; 3RWQ; X-ray; 2.55 A; A=51-359.
DR   PDB; 3SC1; X-ray; 2.70 A; A=50-359.
DR   PDB; 4A06; X-ray; 2.00 A; A=50-359.
DR   PDB; 4A07; X-ray; 1.85 A; A=50-359.
DR   PDB; 4AW0; X-ray; 1.43 A; A=51-359.
DR   PDB; 4AW1; X-ray; 1.68 A; A=51-359.
DR   PDB; 4CT1; X-ray; 1.85 A; A=50-359.
DR   PDB; 4CT2; X-ray; 1.25 A; A=50-359.
DR   PDB; 4RQK; X-ray; 1.55 A; A=50-359.
DR   PDB; 4RQV; X-ray; 1.50 A; A=50-359.
DR   PDB; 4RRV; X-ray; 1.41 A; A=50-359.
DR   PDB; 4XX9; X-ray; 1.40 A; A=50-359.
DR   PDB; 5ACK; X-ray; 1.24 A; A=50-359.
DR   PDB; 5HKM; X-ray; 2.10 A; A=51-359.
DR   PDB; 5HNG; X-ray; 3.01 A; A=51-359.
DR   PDB; 5HO7; X-ray; 3.00 A; A=51-359.
DR   PDB; 5HO8; X-ray; 2.70 A; A=51-359.
DR   PDB; 5LVL; X-ray; 1.40 A; A=50-359.
DR   PDB; 5LVM; X-ray; 1.26 A; A=50-359.
DR   PDB; 5LVN; X-ray; 1.38 A; A=50-359.
DR   PDB; 5LVO; X-ray; 1.09 A; A=50-359.
DR   PDB; 5LVP; X-ray; 2.50 A; A/B/C/D=50-359.
DR   PDB; 5MRD; X-ray; 1.41 A; A=50-359.
DR   PDB; 6WJQ; X-ray; 2.71 A; C/D=2-16.
DR   PDBsum; 1H1W; -.
DR   PDBsum; 1OKY; -.
DR   PDBsum; 1OKZ; -.
DR   PDBsum; 1UU3; -.
DR   PDBsum; 1UU7; -.
DR   PDBsum; 1UU8; -.
DR   PDBsum; 1UU9; -.
DR   PDBsum; 1UVR; -.
DR   PDBsum; 1W1D; -.
DR   PDBsum; 1W1G; -.
DR   PDBsum; 1W1H; -.
DR   PDBsum; 1Z5M; -.
DR   PDBsum; 2BIY; -.
DR   PDBsum; 2PE0; -.
DR   PDBsum; 2PE1; -.
DR   PDBsum; 2PE2; -.
DR   PDBsum; 2R7B; -.
DR   PDBsum; 2VKI; -.
DR   PDBsum; 2XCH; -.
DR   PDBsum; 2XCK; -.
DR   PDBsum; 3H9O; -.
DR   PDBsum; 3HRC; -.
DR   PDBsum; 3HRF; -.
DR   PDBsum; 3ION; -.
DR   PDBsum; 3IOP; -.
DR   PDBsum; 3NAX; -.
DR   PDBsum; 3NAY; -.
DR   PDBsum; 3NUN; -.
DR   PDBsum; 3NUS; -.
DR   PDBsum; 3NUU; -.
DR   PDBsum; 3NUY; -.
DR   PDBsum; 3ORX; -.
DR   PDBsum; 3ORZ; -.
DR   PDBsum; 3OTU; -.
DR   PDBsum; 3PWY; -.
DR   PDBsum; 3QC4; -.
DR   PDBsum; 3QCQ; -.
DR   PDBsum; 3QCS; -.
DR   PDBsum; 3QCX; -.
DR   PDBsum; 3QCY; -.
DR   PDBsum; 3QD0; -.
DR   PDBsum; 3QD3; -.
DR   PDBsum; 3QD4; -.
DR   PDBsum; 3RCJ; -.
DR   PDBsum; 3RWP; -.
DR   PDBsum; 3RWQ; -.
DR   PDBsum; 3SC1; -.
DR   PDBsum; 4A06; -.
DR   PDBsum; 4A07; -.
DR   PDBsum; 4AW0; -.
DR   PDBsum; 4AW1; -.
DR   PDBsum; 4CT1; -.
DR   PDBsum; 4CT2; -.
DR   PDBsum; 4RQK; -.
DR   PDBsum; 4RQV; -.
DR   PDBsum; 4RRV; -.
DR   PDBsum; 4XX9; -.
DR   PDBsum; 5ACK; -.
DR   PDBsum; 5HKM; -.
DR   PDBsum; 5HNG; -.
DR   PDBsum; 5HO7; -.
DR   PDBsum; 5HO8; -.
DR   PDBsum; 5LVL; -.
DR   PDBsum; 5LVM; -.
DR   PDBsum; 5LVN; -.
DR   PDBsum; 5LVO; -.
DR   PDBsum; 5LVP; -.
DR   PDBsum; 5MRD; -.
DR   PDBsum; 6WJQ; -.
DR   AlphaFoldDB; O15530; -.
DR   SMR; O15530; -.
DR   BioGRID; 111196; 149.
DR   DIP; DIP-38372N; -.
DR   ELM; O15530; -.
DR   IntAct; O15530; 144.
DR   MINT; O15530; -.
DR   STRING; 9606.ENSP00000344220; -.
DR   BindingDB; O15530; -.
DR   ChEMBL; CHEMBL2534; -.
DR   DrugBank; DB07132; 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA.
DR   DrugBank; DB06932; 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine.
DR   DrugBank; DB07300; 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine.
DR   DrugBank; DB07456; 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione.
DR   DrugBank; DB07457; 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE.
DR   DrugBank; DB07033; 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE.
DR   DrugBank; DB01933; 7-Hydroxystaurosporine.
DR   DrugBank; DB03777; Bisindolylmaleimide I.
DR   DrugBank; DB01946; Bisindolylmaleimide VIII.
DR   DrugBank; DB00482; Celecoxib.
DR   DrugBank; DB04522; Dexfosfoserine.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugCentral; O15530; -.
DR   GuidetoPHARMACOLOGY; 1519; -.
DR   MoonDB; O15530; Predicted.
DR   iPTMnet; O15530; -.
DR   PhosphoSitePlus; O15530; -.
DR   BioMuta; PDPK1; -.
DR   CPTAC; CPTAC-1052; -.
DR   CPTAC; CPTAC-1540; -.
DR   EPD; O15530; -.
DR   jPOST; O15530; -.
DR   MassIVE; O15530; -.
DR   MaxQB; O15530; -.
DR   PaxDb; O15530; -.
DR   PeptideAtlas; O15530; -.
DR   PRIDE; O15530; -.
DR   ProteomicsDB; 34858; -.
DR   ProteomicsDB; 48736; -. [O15530-1]
DR   ProteomicsDB; 48737; -. [O15530-2]
DR   ProteomicsDB; 48738; -. [O15530-3]
DR   ProteomicsDB; 48739; -. [O15530-4]
DR   Antibodypedia; 3794; 993 antibodies from 46 providers.
DR   DNASU; 5170; -.
DR   Ensembl; ENST00000268673.11; ENSP00000268673.7; ENSG00000140992.19. [O15530-4]
DR   Ensembl; ENST00000342085.9; ENSP00000344220.4; ENSG00000140992.19. [O15530-1]
DR   Ensembl; ENST00000441549.7; ENSP00000395357.3; ENSG00000140992.19. [O15530-5]
DR   GeneID; 5170; -.
DR   KEGG; hsa:5170; -.
DR   MANE-Select; ENST00000342085.9; ENSP00000344220.4; NM_002613.5; NP_002604.1.
DR   UCSC; uc002cqs.5; human. [O15530-1]
DR   CTD; 5170; -.
DR   DisGeNET; 5170; -.
DR   GeneCards; PDPK1; -.
DR   HGNC; HGNC:8816; PDPK1.
DR   HPA; ENSG00000140992; Low tissue specificity.
DR   MIM; 605213; gene.
DR   neXtProt; NX_O15530; -.
DR   OpenTargets; ENSG00000140992; -.
DR   PharmGKB; PA33160; -.
DR   VEuPathDB; HostDB:ENSG00000140992; -.
DR   eggNOG; KOG0592; Eukaryota.
DR   GeneTree; ENSGT00940000155267; -.
DR   InParanoid; O15530; -.
DR   OMA; GYPSIRA; -.
DR   OrthoDB; 1157543at2759; -.
DR   PhylomeDB; O15530; -.
DR   TreeFam; TF105423; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O15530; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-165158; Activation of AKT2.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SABIO-RK; O15530; -.
DR   SignaLink; O15530; -.
DR   SIGNOR; O15530; -.
DR   BioGRID-ORCS; 5170; 549 hits in 1121 CRISPR screens.
DR   ChiTaRS; PDPK1; human.
DR   EvolutionaryTrace; O15530; -.
DR   GeneWiki; Phosphoinositide-dependent_kinase-1; -.
DR   GenomeRNAi; 5170; -.
DR   Pharos; O15530; Tchem.
DR   PRO; PR:O15530; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; O15530; protein.
DR   Bgee; ENSG00000140992; Expressed in secondary oocyte and 194 other tissues.
DR   ExpressionAtlas; O15530; baseline and differential.
DR   Genevisible; O15530; HS.
DR   GO; GO:0042995; C:cell projection; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0004676; F:3-phosphoinositide-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016004; F:phospholipase activator activity; IMP:BHF-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:MGI.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:BHF-UCL.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0003323; P:type B pancreatic cell development; IEA:Ensembl.
DR   CDD; cd01262; PH_PDK1; 1.
DR   CDD; cd05581; STKc_PDK1; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033931; PDK1-typ_PH.
DR   InterPro; IPR039046; PDPK1.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF14593; PH_3; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; ATP-binding;
KW   Cell junction; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..556
FT                   /note="3-phosphoinositide-dependent protein kinase 1"
FT                   /id="PRO_0000086500"
FT   DOMAIN          82..342
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          459..550
FT                   /note="PH"
FT   REGION          26..80
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          113..157
FT                   /note="PIF-pocket"
FT                   /evidence="ECO:0000305|PubMed:22999883"
FT   COMPBIAS        26..42
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        205
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         92..94
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:12169624,
FT                   ECO:0000269|PubMed:15741170, ECO:0000269|PubMed:22999883"
FT   BINDING         111
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:12169624,
FT                   ECO:0000269|PubMed:15741170, ECO:0000269|PubMed:22999883"
FT   BINDING         160..162
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:12169624,
FT                   ECO:0000269|PubMed:15741170, ECO:0000269|PubMed:22999883"
FT   BINDING         166
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:12169624,
FT                   ECO:0000269|PubMed:15741170, ECO:0000269|PubMed:22999883"
FT   BINDING         209
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:22999883"
FT   BINDING         223
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:12169624,
FT                   ECO:0000269|PubMed:15741170, ECO:0000269|PubMed:22999883"
FT   MOD_RES         9
FT                   /note="Phosphotyrosine; by SRC and INSR"
FT                   /evidence="ECO:0000269|PubMed:11481331,
FT                   ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:16314505"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MOD_RES         241
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10455013,
FT                   ECO:0000269|PubMed:11481331, ECO:0000269|PubMed:15772071,
FT                   ECO:0000269|PubMed:16780920, ECO:0000269|Ref.8"
FT   MOD_RES         304
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2A0"
FT   MOD_RES         354
FT                   /note="Phosphothreonine; by MELK"
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MOD_RES         373
FT                   /note="Phosphotyrosine; by SRC and INSR"
FT                   /evidence="ECO:0000269|PubMed:11481331,
FT                   ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:16314505"
FT   MOD_RES         376
FT                   /note="Phosphotyrosine; by SRC and INSR"
FT                   /evidence="ECO:0000269|PubMed:11481331,
FT                   ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:16314505"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MOD_RES         394
FT                   /note="Phosphoserine; by MAP3K5"
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MOD_RES         396
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10455013,
FT                   ECO:0000269|PubMed:15743829"
FT   MOD_RES         398
FT                   /note="Phosphoserine; by MAP3K5"
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MOD_RES         410
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MOD_RES         501
FT                   /note="Phosphoserine; by PKC/PRKCQ"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2A0"
FT   MOD_RES         513
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16780920"
FT   MOD_RES         529
FT                   /note="Phosphoserine; by PKC/PRKCQ"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2A0"
FT   VAR_SEQ         1..50
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004894"
FT   VAR_SEQ         110..237
FT                   /note="IKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSY
FT                   AKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQ
FT                   ITDFGTAKVLSPESKQA -> T (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041902"
FT   VAR_SEQ         238..263
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9445477"
FT                   /id="VSP_004895"
FT   VAR_SEQ         448..556
FT                   /note="WHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIP
FT                   WSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ
FT                   -> CLTGRII (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_044796"
FT   MUTAGEN         9
FT                   /note="Y->F: Slight reduction in pervanadate-stimulated
FT                   tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11481331"
FT   MUTAGEN         25
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MUTAGEN         241
FT                   /note="S->A: No activation."
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MUTAGEN         277
FT                   /note="A->V: 3-fold increase in kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10364160"
FT   MUTAGEN         354
FT                   /note="T->A: Abolishes phosphorylation by MELK."
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MUTAGEN         373
FT                   /note="Y->F: Reduction in basal activity."
FT                   /evidence="ECO:0000269|PubMed:11481331"
FT   MUTAGEN         376
FT                   /note="Y->F: Reduction in basal activity."
FT                   /evidence="ECO:0000269|PubMed:11481331"
FT   MUTAGEN         393
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MUTAGEN         394
FT                   /note="S->A: Abolishes phosphorylation by MAP3K5; when
FT                   associated with A-398."
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MUTAGEN         396
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MUTAGEN         398
FT                   /note="S->A: Abolishes phosphorylation by MAP3K5; when
FT                   associated with A-394."
FT                   /evidence="ECO:0000269|PubMed:22544756"
FT   MUTAGEN         410
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:10455013"
FT   MUTAGEN         474
FT                   /note="R->A: No PDGF-dependent translocation to the
FT                   membrane."
FT                   /evidence="ECO:0000269|PubMed:9637919"
FT   MUTAGEN         513
FT                   /note="T->E: Enhanced kinase activity towards PKB."
FT                   /evidence="ECO:0000269|PubMed:20978239"
FT   TURN            7..9
FT                   /evidence="ECO:0007829|PDB:6WJQ"
FT   HELIX           79..81
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          82..90
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          95..101
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   TURN            102..104
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          107..114
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           115..120
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           124..136
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          145..150
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          152..159
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          163..166
FT                   /evidence="ECO:0007829|PDB:3PWY"
FT   HELIX           167..174
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           179..198
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           224..226
FT                   /evidence="ECO:0007829|PDB:3ORX"
FT   TURN            232..235
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          238..240
FT                   /evidence="ECO:0007829|PDB:3OTU"
FT   HELIX           246..248
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           251..256
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           261..277
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           287..295
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:3QD3"
FT   HELIX           307..316
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           321..323
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           333..337
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           340..342
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           347..352
FT                   /evidence="ECO:0007829|PDB:5LVO"
FT   HELIX           412..415
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          416..420
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          423..426
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   HELIX           432..445
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   HELIX           449..451
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   TURN            452..454
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          457..467
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          470..479
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   TURN            480..482
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          483..488
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   TURN            489..492
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          493..498
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          505..518
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   STRAND          521..526
FT                   /evidence="ECO:0007829|PDB:1W1G"
FT   HELIX           532..547
FT                   /evidence="ECO:0007829|PDB:1W1G"
SQ   SEQUENCE   556 AA;  63152 MW;  ED8C0306DC4D0653 CRC64;
     MARTTSQLYD AVPIQSSVVL CSCPSPSMVR TQTESSTPPG IPGGSRQGPA MDGTAAEPRP
     GAGSLQHAQP PPQPRKKRPE DFKFGKILGE GSFSTVVLAR ELATSREYAI KILEKRHIIK
     ENKVPYVTRE RDVMSRLDHP FFVKLYFTFQ DDEKLYFGLS YAKNGELLKY IRKIGSFDET
     CTRFYTAEIV SALEYLHGKG IIHRDLKPEN ILLNEDMHIQ ITDFGTAKVL SPESKQARAN
     SFVGTAQYVS PELLTEKSAC KSSDLWALGC IIYQLVAGLP PFRAGNEYLI FQKIIKLEYD
     FPEKFFPKAR DLVEKLLVLD ATKRLGCEEM EGYGPLKAHP FFESVTWENL HQQTPPKLTA
     YLPAMSEDDE DCYGNYDNLL SQFGCMQVSS SSSSHSLSAS DTGLPQRSGS NIEQYIHDLD
     SNSFELDLQF SEDEKRLLLE KQAGGNPWHQ FVENNLILKM GPVDKRKGLF ARRRQLLLTE
     GPHLYYVDPV NKVLKGEIPW SQELRPEAKN FKTFFVHTPN RTYYLMDPSG NAHKWCRKIQ
     EVWRQRYQSH PDAAVQ
//
